Zimmer Biomet's Spine Business to Get a Boost with LDR Buy
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 6:00AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) has entered into a definitive agreement to acquire LDR Holding Corp. (LDRH) for a total deal value of $1 billion.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), ZBH: 119.23 (-0.17), LDRH: 36.98 (+0.07)
NuVasive to Strengthen Spine Service Line with Biotronic Buy
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:17AM CDT
NuVasive, Inc. (NUVA) recently entered into a definitive agreement to acquire privately held Biotronic NeuroNetwork.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), BAX: 44.49 (-0.26), NUVA: 58.98 (-1.03)
Abaxis (ABAX): Solid Veterinary Show Despite Global Hiccups
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 5:01AM CDT
On Jun 3, 2016, we issued an updated research report on Abaxis, Inc. (ABAX). The stock currently carries a Zacks Rank #4 (Sell).
ICUI: 107.33 (-0.80), ABAX: 45.53 (-1.36), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
Medtronic (MDT) Posts Solid Q4; Covidien Synergy Continues
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 6:31AM CDT
On Jun 3, 2016, we issued an updated research report on Medtronic plc (MDT).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), MDT: 85.70 (-0.08), LMAT: 15.03 (-0.06)
Medtronic (MDT) Beats Q4 Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Tue May 31, 8:01AM CDT
Medtronic's (MDT) fourth-quarter fiscal 2016 adjusted earnings per share (EPS) came in at $1.27, a penny ahead of the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), MDT: 85.70 (-0.08), LMAT: 15.03 (-0.06)
NuVasive Poised on Solid International Sales, Scope in Spine
Zacks Equity Research - Zacks Investment Research - Tue May 31, 6:01AM CDT
On May 30, 2016, we updated our research report on NuVasive, Inc. (NUVA).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
Medtronic (MDT): Will Currency Woes Hurt Q4 As Well?
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:26AM CDT
On May 26, 2016, we issued an updated research report on Medtronic plc (MDT).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), MDT: 85.70 (-0.08), LMAT: 15.03 (-0.06)
Abaxis (ABAX) Posts Solid Q4 amid International Headwind
Zacks Equity Research - Zacks Investment Research - Wed May 25, 5:28AM CDT
On May 18, 2016, we issued an updated research report on Abaxis, Inc. (ABAX).
ICUI: 107.33 (-0.80), ABAX: 45.53 (-1.36), LMAT: 15.03 (-0.06), NUVA: 58.98 (-1.03)
Zimmer Biomet: Strong Q1, Integration Synergy Continues
Zacks Equity Research - Zacks Investment Research - Mon May 23, 6:39AM CDT
On May 23, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
BSX: 23.02 (-0.30), ICUI: 107.33 (-0.80), ZBH: 119.23 (-0.17), NUVA: 58.98 (-1.03)
Medical Stocks' Q1 Earnings Releases on May 10: ICUI, ZLTQ
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:44AM CDT
The two popular names in the medical space, gearing up to report results on May 10, are ICUI and ZLTQ.
ICUI: 107.33 (-0.80), ZLTQ: 28.51 (-0.85)
ICU Medical, Inc. Announces Time of First Quarter 2016 Earnings Call
GlobeNewswire - Tue Apr 19, 3:05PM CDT
ICU Medical, Inc., (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced the time of its first quarter 2016 earnings release conference call.
ICUI: 107.33 (-0.80)
B. Braun and ICU Medical Sign Expanded Long-Term International Distribution Agreement
PR Newswire - Mon Mar 21, 7:00AM CDT
ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term distribution agreement with B. Braun Melsungen AG, giving B. Braun distribution rights to promote ICU Medical's SwabCap® disinfecting cap for needlefree connectors in selected countries outside the United States. Under the expanded agreement, customers will be able to purchase the SwabCap family of products from B. Braun in more than 30 countries around the world.
ICUI: 107.33 (-0.80)
Shares of ICUI Down 13.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 04, 5:48PM CST
SmarTrend identified a Downtrend for ICU Medical (NASDAQ:ICUI) on January 7th, 2016 at $106.19. In approximately 2 months, ICU Medical has returned 13.29% as of today's recent price of $92.07.
ICUI: 107.33 (-0.80)
Omnicell: Sales, Acquisitions Impress; Margin Pressure Lingers
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 1:50PM CST
On Feb 17, 2016, we issued an updated research report on Omnicell, Inc. (OMCL).
ICUI: 107.33 (-0.80), INSY: 13.99 (-2.04), BAX: 44.49 (-0.26), OMCL: 33.68 (-0.17)
ICU Medical Down 18.2% Since SmarTrend Downtrend Call (ICUI)
Comtex SmarTrend(R) - Fri Feb 05, 6:52PM CST
SmarTrend identified a Downtrend for ICU Medical (NASDAQ:ICUI) on January 7th, 2016 at $106.19. In approximately 4 weeks, ICU Medical has returned 18.20% as of today's recent price of $86.86.
ICUI: 107.33 (-0.80)
ICU Medical beats 4Q profit forecasts
Automated Insights - Wed Feb 03, 4:59PM CST
SAN CLEMENTE, Calif. (AP) _ ICU Medical Inc. (ICUI) on Wednesday reported fourth-quarter net income of $5.5 million.
ICUI: 107.33 (-0.80)
ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2015 Results
GlobeNewswire - Wed Feb 03, 3:10PM CST
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced financial results for the fourth quarter and fiscal year ended December 31, 2015.
ICUI: 107.33 (-0.80)
ICU Medical, Inc. Announces Time of Fourth Quarter and Fiscal Year 2015 Earnings Call
GlobeNewswire - Fri Jan 22, 6:30AM CST
ICU Medical, Inc., (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, today announced the time of its fourth quarter and fiscal year 2015 earnings release conference call.
ICUI: 107.33 (-0.80)
New Study Shows ICU Medical's SwabCap® Reduced Central Line-Associated Bloodstream Infections and Blood Culture Contamination, Corresponding To $3.2 Million Annual Savings
PR Newswire - Wed Jan 13, 7:00AM CST
ICU Medical Inc. (NASDAQ: ICUI) today announced that a new study published in the December 2015 issue of the peer-reviewed journal Infection Control & Hospital Epidemiology showed that the company's SwabCap® disinfecting cap for needlefree connectors reduced central line-associated bloodstream infections (HA-CLABSI) and blood culture contamination (BCC) among hematology-oncology patients.1 The study by clinicians at New York City's Memorial Sloan Kettering Cancer Center found that the reduction in HA-CLABSI and BCC using of SwabCap "corresponded to an annual savings of $3.2 million in direct medical costs."
ICUI: 107.33 (-0.80)
Cepheid's GeneXpert System to be Distributed by Henry Schein
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 1:30PM CST
The agreement will allow Henry Schein (HSIC) to distribute Cepheid's (CPHD) fully integrated and automated on-demand molecular system GeneXpert to non-acute care laboratories across the U.S.
ICUI: 107.33 (-0.80), NXTM: 20.63 (-0.36), CPHD: 28.27 (-0.60), HSIC: 178.35 (-2.36)